Literature DB >> 26541558

Metacognition moderates the relationship of disturbances in attachment with severity of borderline personality disorder among persons in treatment of substance use disorders.

Jared Outcalt1, Giancarlo Dimaggio2, Raffaele Popolo2, Kelly Buck3, Kelly A Chaudoin-Patzoldt4, Marina Kukla5, Kyle L Olesek2, Paul H Lysaker6.   

Abstract

OBJECTIVES: Borderline personality disorder traits have been observed to be linked with both insecure attachment styles as well as deficits in mentalizing and metacognition. Less is known, however, about how attachment style does or does not interact with deficits in mentalizing and metacognition to create, sustain, or influence levels of borderline personality disorder traits. In this study, we examined the hypothesis that metacognitive mastery, which is the ability to use knowledge about mental states of self and others to cope with distress and solve social problems, moderates the relationship of anxious attachment style with the severity of borderline personality disorder traits.
METHODS: Concurrent assessments were gathered of metacognitive mastery using the Metacognitive Assessment Scale Abbreviated, anxious attachment style using the Experiences of in Close Relationships Scale, and borderline personality disorder traits using the Structured Clinical Interview for DSM-IV Axis II Disorders. Participants were 59 adults in an early phase of recovery from substance use disorders in a residential setting.
RESULTS: Multiple regression revealed that metacognitive mastery moderated the relationship of anxious attachment style with the number of borderline personality disorder traits. A median split of the anxious attachment and metacognitive mastery scores was performed yielding 4 groups. An analysis of covariance revealed that participants with higher levels of anxious attachment and poorer metacognitive mastery had more borderline personality disorder traits did than the other groups after controlling for levels of psychopathology.
CONCLUSION: Insecure attachment may be associated with higher number of borderline personality disorder traits in the presence of deficits in metacognitive mastery. Patients with substance use and borderline personality disorder traits may benefit from treatment which addresses metacognitive mastery. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2015        PMID: 26541558     DOI: 10.1016/j.comppsych.2015.10.002

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  6 in total

Review 1.  Promoting recovery from severe mental illness: Implications from research on metacognition and metacognitive reflection and insight therapy.

Authors:  Paul Henry Lysaker; Jay A Hamm; Ilanit Hasson-Ohayon; Michelle L Pattison; Bethany L Leonhardt
Journal:  World J Psychiatry       Date:  2018-03-22

2.  Path analysis from COVID-19 perceptions to psychological health: The roles of critical distance and mastery.

Authors:  Bruno Faustino; António Branco Vasco; António Farinha-Fernandes; João Delgado; José Carlos Guerreiro; Marta Matos
Journal:  Clin Psychol Psychother       Date:  2022-03-21

3.  Metacognition and Intersubjectivity: Reconsidering Their Relationship Following Advances From the Study of Persons With Psychosis.

Authors:  Ilanit Hasson-Ohayon; Andrew Gumley; Hamish McLeod; Paul H Lysaker
Journal:  Front Psychol       Date:  2020-03-25

Review 4.  Alcohol Use Disorder and Antisocial and Borderline Personality Disorders.

Authors:  Ashley C Helle; Ashley L Watts; Timothy J Trull; Kenneth J Sher
Journal:  Alcohol Res       Date:  2019-12-30

5.  Attachment, Mentalization, and Criterion B of the Alternative DSM-5 Model for Personality Disorders (AMPD).

Authors:  Ericka Ball Cooper; Jaime L Anderson; Carla Sharp; Hillary A Langley; Amanda Venta
Journal:  Borderline Personal Disord Emot Dysregul       Date:  2021-08-02

6.  Elevated empathy in adults following childhood trauma.

Authors:  David M Greenberg; Simon Baron-Cohen; Nora Rosenberg; Peter Fonagy; Peter J Rentfrow
Journal:  PLoS One       Date:  2018-10-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.